Can a simple urine test prevent kidney failure in sepsis?
NCT ID NCT04434209
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether using a urine biomarker test (NephroCheck) to guide treatment could reduce kidney injury, dialysis, or death in sepsis patients. The trial planned to enroll many participants but was stopped early after only 19 people joined. The idea was to catch kidney stress early and adjust care, but the early termination means we cannot draw firm conclusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NephroCheck® test (a urine biomarker test to assess kidney stress)
What this could lead to
If successful, this approach could help doctors identify sepsis patients at risk of kidney injury earlier and tailor care to prevent kidney damage.
What could go wrong
The trial was terminated early with only 19 participants, so results are very limited. The test may not improve outcomes in larger or different patient groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Sint-Jan Brugge-Oostende, Intensieve Zorgen, Ruddershove 10
Bruges, West-Vlaanderen, 8000, Belgium
-
Brigham and Womens Hospital, 75 Francis Street
Boston, Massachusetts, 02115, United States
-
CHRU Dijon Complexe Du Bocage, Department Infectiologie, 14 rue Gaffarel
Dijon, 21079, France
-
CHU Angers, 4 Rue Larrey
Angers, Maine-et-Loire, 49100, France
-
Centre Hospitalier de Béthune, Service de Réanimation et Surveillance continue, 27 rue Delbecque
Béthune, Pas-de-Calais, 62408, France
-
Hopital Cochin, 27 Rue Du Faubourg Saint Jacques
Paris, 75679, France
-
Hôpital Erasme, Soins Intensifs, Route de Lennik 808
Brussels, 1070, Belgium
-
LSU Health Sciences Center, 1541 Kings Highway
Shreveport, Louisiana, 71130, United States
-
Memorial Sloan Kettering Cancer Center, 1275 York Avenue
New York, New York, 10065, United States
-
Universitatsklinikum Leipzig, Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Liebigstraße 20
Leipzig, Saxony, 04103, Germany
-
Universitatsklinikum Munster, Albert-Schweitzer-Campus 1
Münster, 48149, Germany
-
University Clinic Heidelberg, Klinik für Anaesthesiologie, Im Neuenheimer Feld 110
Heidelberg, Baden-Wurttemberg, 69120, Germany